Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 3561-3570 of 8049

  • Results filtered:
  • Locations: Rochester, MN
Edit search filters
  1. Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

    Rochester, MN

  3. Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

    Rochester, MN

  4. Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk (CalmiGo)

    Rochester, MN

  5. Sym021 in Combination with Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients with Advanced Biliary Tract Carcinomas

    Rochester, MN

  6. A Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB8802 in Healthy Volunteers and in Patients with Enteric Hyperoxaluria

    Rochester, MN

  7. PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

    Rochester, MN

  8. Hyperbaric Oxygen for Ulcerative Colitis

    Rochester, MN

  9. Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML

    Rochester, MN

  10. I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer